MCID: GRV001
MIFTS: 57

Graves' Disease

Categories: Rare diseases, Endocrine diseases, Immune diseases

Aliases & Classifications for Graves' Disease

MalaCards integrated aliases for Graves' Disease:

Name: Graves' Disease 12 50 25 29 14
Graves Disease 12 25 52 42 69
Exophthalmic Goiter 12 50 25
Toxic Diffuse Goiter 25 69
Basedow's Disease 12 25
Basedow Disease 50 25
Autoimmune Hyperthyroidism 25
Toxic Multinodular Goiter 69
Graves' Hyperthyroidism 50
Grave's Disease 12
Parry Disease 50

Classifications:



Summaries for Graves' Disease

NIH Rare Diseases : 50 graves' disease is an autoimmune disorder that leads to overactivity of the thyroid gland (hyperthyroidism). it is caused by an abnormal immune system response that causes the thyroid gland to produce too much thyroid hormones. graves disease is the most common cause of hyperthyroidism and occurs most often in women over age 20. however, the disorder may occur at any age and may affect males as well. treatment may include radioiodine therapy, antithyroid drugs, and/or thyroid surgery. last updated: 4/21/2015

MalaCards based summary : Graves' Disease, also known as graves disease, is related to lymphoma and malignant hyperthermia. An important gene associated with Graves' Disease is SLC25A16 (Solute Carrier Family 25 Member 16), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Influenza A. The drugs Propylthiouracil and Bimatoprost have been mentioned in the context of this disorder. Affiliated tissues include thyroid, eye and t cells, and related phenotypes are endocrine/exocrine gland and hematopoietic system

Disease Ontology : 12 An autoimmune disease of endocrine system that involves production of excessive amount of thyroid hormones, located in thyroid gland.

Genetics Home Reference : 25 Graves disease is a condition that affects the function of the thyroid, which is a butterfly-shaped gland in the lower neck. The thyroid makes hormones that help regulate a wide variety of critical body functions. For example, thyroid hormones influence growth and development, body temperature, heart rate, menstrual cycles, and weight. In people with Graves disease, the thyroid is overactive and makes more hormones than the body needs. The condition usually appears in mid-adulthood, although it may occur at any age.

Wikipedia : 72 Graves\' disease, also known as toxic diffuse goiter, is an autoimmune disease that affects the thyroid.... more...

Related Diseases for Graves' Disease

Diseases in the Graves' Disease family:

Graves Disease 1 Graves Disease 2

Diseases related to Graves' Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 309)
id Related Disease Score Top Affiliating Genes
1 lymphoma 29.9 CTLA4 IFNG IL4 TG TPO TSHR
2 malignant hyperthermia 29.4 CTLA4 IFNG IL2RA IL4
3 rheumatoid arthritis 28.4 CTLA4 FCRL3 HLA-DQA1 ICAM1 IFNG IL4
4 pseudohypoparathyroidism 28.2 CD40 CTLA4 FCRL3 IFNG IL4 PTPN22
5 systemic lupus erythematosus 26.4 CD40 CTLA4 FASLG FCRL3 HLA-DQA1 ICAM1
6 graves disease 1 12.1
7 graves disease 2 11.9
8 hyperthyroidism 11.2
9 exophthalmos 11.1
10 digeorge syndrome 11.1
11 adenohypophysitis 10.9 TG TPO
12 maxillary sinus adenoid cystic carcinoma 10.9 TG TPO
13 autoimmune thyroid disease 3 10.9
14 myopathy - thyrotoxic 10.9
15 cln4 disease 10.8
16 chronic polyneuropathy 10.8 TG TSHR
17 kidney disease 10.8 TG TSHR
18 nephrogenic systemic fibrosis 10.8 TG TPO TSHR
19 rhabdomyosarcoma, embryonal, 2 10.8 TG TPO
20 clopidogrel resistance 10.8 CTLA4 PTPN22
21 atypical juvenile parkinsonism 10.8 CTLA4 HLA-DQA1
22 meningovascular neurosyphilis 10.8 TG TPO TSHR
23 bladder diffuse clear cell adenocarcinoma 10.8 TG TPO TSHR
24 autoinflammation with arthritis and dyskeratosis 10.8 CTLA4 PTPN22 TPO
25 primary bacterial infectious disease 10.8 TG TPO TSHR
26 hypermobility syndrome 10.7 CTLA4 PTPN22 TPO
27 thyroiditis 10.7
28 gastrointestinal system cancer 10.7 TG TPO TSHR
29 thyrotoxic periodic paralysis 1 10.7
30 hyperthyroidism, nonautoimmune 10.7
31 luxation of globe 10.7
32 thyrotoxic periodic paralysis 2 10.7
33 methimazole antenatal exposure 10.7
34 autoimmune thyroid disease 2 10.7
35 myoclonic astatic epilepsy 10.7 IFNG IL4
36 chorea, hereditary benign 10.7 TG TPO TSHR
37 panhypophysitis 10.7 TG TSHR
38 non-distal trisomy 10q 10.7 TG TPO TSHR
39 conjunctival deposit 10.7 CTLA4 TG TPO TSHR
40 glaucomatocyclitic crisis 10.6 CTLA4 TSHR
41 acute gonococcal prostatitis 10.6 CTLA4 IFNG IL4
42 abnormal retinal correspondence 10.5 CTLA4 IFNG IL4
43 specific developmental disorder 10.5 CTLA4 HLA-DQA1 IFNG
44 alport syndrome-intellectual disability-midface hypoplasia-elliptocytosis syndrome 10.5 IL2RA PTPN22
45 tick paralysis 10.5 ICAM1 TG TPO
46 mesenchymal cell neoplasm 10.5 IFNG IL4 PTPN22
47 neonatal stroke 10.4 CTLA4 IFNG IL4
48 frontotemporal dementia and/or amyotrophic lateral sclerosis 4 10.4 DIO2 LMOD1 TG TPO TSHR
49 eye accommodation disease 10.3 IFNG IL2RA IL4
50 hypothyroidism due to deficient transcription factors involved in pituitary development or function 10.3 IFNG IL2RA IL4

Graphical network of the top 20 diseases related to Graves' Disease:



Diseases related to Graves' Disease

Symptoms & Phenotypes for Graves' Disease

MGI Mouse Phenotypes related to Graves' Disease:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.25 UACA CD40 CTLA4 DIO2 FASLG HLA-DQA1
2 hematopoietic system MP:0005397 10.24 CD40 CTLA4 FASLG FGFR1OP HLA-DQA1 ICAM1
3 homeostasis/metabolism MP:0005376 10.17 CD40 CTLA4 DIO2 FASLG FGFR1OP ICAM1
4 immune system MP:0005387 10.1 TSHR UACA CD40 CTLA4 FASLG FGFR1OP
5 digestive/alimentary MP:0005381 10.03 CTLA4 DIO2 FASLG ICAM1 IFNG IL2RA
6 renal/urinary system MP:0005367 9.7 CD40 DIO2 FASLG IFNG IL4 PTPN22
7 respiratory system MP:0005388 9.5 CTLA4 FASLG IFNG IL2RA IL4 PTPN22
8 vision/eye MP:0005391 9.23 IL2RA IL4 TPO TSHR FASLG FGFR1OP

Drugs & Therapeutics for Graves' Disease

Drugs for Graves' Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 188)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Propylthiouracil Approved Phase 4,Phase 3,Phase 2 51-52-5 657298
2
Bimatoprost Approved, Investigational Phase 4,Phase 3 155206-00-1 5311027
3
Latanoprost Approved, Investigational Phase 4 130209-82-4 5282380 5311221
4
Timolol Approved Phase 4 26839-75-8 33624 5478
5
Travoprost Approved Phase 4 157283-68-6 5282226
6
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3 83-43-2 6741
7
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3 50-24-8 5755
8
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3 53-03-2 5865
9
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
10
Acetylcholine Approved Phase 4,Phase 2,Phase 3 51-84-3 187
11
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 1 50-02-2 5743
12
Diclofenac Approved, Vet_approved Phase 4,Phase 3 15307-86-5 3033
13
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
14
Propranolol Approved, Investigational Phase 4 525-66-6 4946
15
Dinoprost Tromethamine Approved, Vet_approved Phase 4 38562-01-5 5282415
16
Ephedrine Approved Phase 4 299-42-3 9294
17
Pseudoephedrine Approved Phase 4 90-82-4 7028
18
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 126941
19
rituximab Approved Phase 4,Phase 2,Phase 3,Phase 1 174722-31-7 10201696
20
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741 24759
21
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
22
leucovorin Approved, Nutraceutical Phase 4 58-05-9 143 6006
23
Maleic acid Experimental Phase 4 110-16-7 444266
24
Iodine Investigational Phase 4,Phase 3,Phase 2 7553-56-2 807
25
Dinoprost Investigational Phase 4 551-11-1 5283078
26 Antimetabolites Phase 4,Phase 3
27 Antithyroid Agents Phase 4,Phase 3,Phase 1,Phase 2
28 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1
29 Hormones Phase 4,Phase 2,Phase 3,Phase 1
30 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1
31 Adrenergic Agents Phase 4
32 Adrenergic Antagonists Phase 4
33 Adrenergic beta-Antagonists Phase 4
34 Anti-Arrhythmia Agents Phase 4
35 Antihypertensive Agents Phase 4,Phase 3
36 Neurotransmitter Agents Phase 4,Phase 2,Phase 3
37 Ophthalmic Solutions Phase 4,Phase 2
38 Tetrahydrozoline Phase 4,Phase 2
39 Antiemetics Phase 4,Phase 2,Phase 3,Phase 1
40 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Phase 1
41 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 3,Phase 1
42 Autonomic Agents Phase 4,Phase 2,Phase 3,Phase 1
43 Gastrointestinal Agents Phase 4,Phase 2,Phase 3,Phase 1
44 glucocorticoids Phase 4,Phase 2,Phase 3,Phase 1
45 Methylprednisolone acetate Phase 4,Phase 2,Phase 3
46 Methylprednisolone Hemisuccinate Phase 4,Phase 2,Phase 3
47 Neuroprotective Agents Phase 4,Phase 2,Phase 3
48 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1
49 Prednisolone acetate Phase 4,Phase 2,Phase 3
50 Prednisolone hemisuccinate Phase 4,Phase 2,Phase 3

Interventional clinical trials:

(show top 50) (show all 119)

id Name Status NCT ID Phase Drugs
1 The Effect of Early Total Thyroidectomy in the Course of Graves' Orbitopathy Unknown status NCT01056419 Phase 4 Propylthiouracil
2 The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients. Unknown status NCT01927406 Phase 4 Prostaglandin Analog;Timolol
3 A Prospective, Randomized Trial of Intravenous Pulse Versus Sequential Steroid Therapy for Patients With Graves' Orbitopathy Unknown status NCT01969019 Phase 4 methylprednisolone, prednisone
4 Impact of SSKI Pre-Treatment on Blood Loss in Thyroidectomy for Graves Disease Completed NCT00946296 Phase 4 Potassium Iodide
5 Prevention Relapse of Graves' Disease by Intrathyroid Injection of Dexamethasone Completed NCT00917241 Phase 4 MMI combined with IID;MMI
6 Adjuvant Treatment of Graves´ Ophthalmopathy With NSAID (aGO Study) Completed NCT01458600 Phase 4 Diclofenac;Methimazole;L-thyroxin;Propranolol;Metoprolol
7 Antithyroid Drugs During Radioiodine Therapy Completed NCT00150137 Phase 4 Methimazole
8 Block-replacement Therapy During Radioiodine Therapy Completed NCT00150124 Phase 4 MTZ+LT4;Methimazole
9 Prostaglandin F2-alpha Eye Drops in Thyroid Eye Disease (Bima Study) Completed NCT02059655 Phase 4 Bimatoprost;Eye drop solution
10 Is the Routine Pressure Dressing After Thyroidectomy Necessary? Completed NCT00400465 Phase 4
11 Treatment of Upper Eyelid Retraction Related to Thyroid-associated Ophthalmopathy Using Subconjunctival Triamcinolone Injections Completed NCT01599273 Phase 4 subconjunctival triamcinolone injection
12 Rituximab (RTX) Therapy in Patients With Active TAO Recruiting NCT02378298 Phase 4 Rituximab;Iv Methylprednisolone;peroral methylprednisolone and Methotrexate
13 Hyaluronic Acid Gels for Upper Lid Retraction in Active Stage Thyroid Eye Disease Recruiting NCT01738243 Phase 4 Hyaluronic Acid Gel injection;Saline injection
14 Using A Novel Classification System in Intravenous GCs Therapy of TAO: A Multi-central, Randomized, Open, Superior Trial Recruiting NCT03107078 Phase 4 Glucocorticoids
15 Effects of Statins in Graves' Orbitopathy (GO) in Hypercholesterolemic Patients Not yet recruiting NCT03110848 Phase 4 Atorvastatin;Methylprednisolone
16 Combined Radiotherapy and Intravenous Steroids for Early Progressive Thyroid Eye Disease Not yet recruiting NCT02339142 Phase 4 intravenous corticosteroids (methylprednisolone)
17 A Trial to Evaluate the Efficacy of Orbital Radiotherapy in Graves' Orbitopathy Not yet recruiting NCT03098225 Phase 4 Methylprednisolone
18 Use of Botox in the Management of Thyroid Related Upper Eyelid Retraction Withdrawn NCT01272414 Phase 4 Botulinum Toxin Type A;Saline injection
19 The Prospective Study of Standard Treatment of Graves Disease Iodine 131 and Prevention of Adverse Reactions Unknown status NCT01204359 Phase 3
20 Effect of Percutaneous Botulinum Toxin A Injection on Natural Course of Upper Lid Retraction in Thyroid Eye Disease Unknown status NCT00370734 Phase 2, Phase 3 Botulinum toxin A injection
21 Treatment of Soft Tissue Expansion in Inactive Thyroid Eye Disease Patients Using Drops of Prostaglandin Analogues Unknown status NCT02155049 Phase 3 bimatoprost 0.03%
22 Prednisone Versus Doxycycline in the Treatment of Graves' Orbitopathy Unknown status NCT01809444 Phase 2, Phase 3 Prednisone+placebo of Doxycycline;Doxycycline+placebo of Prednisone
23 Comparison of Different Doses of 131I in Severe Graves' Hyperthyroidism Completed NCT01039818 Phase 3
24 Assessing the Impact of the Early and Systematic Hormonal Replacement After Radio-isotopic Ablation of Graves'hyperthyroïdism on Quality of Life, Efficiency and Tolerance Completed NCT01295333 Phase 3 the early prophylactic introduction of low dose of LT4 (50 µg/d) at 15 days post-ablation;The initiation of LT4 as soon as the first biological signs of hypothyroidism.
25 Tocilizumab Treatment in Graves´ Ophthalmopathy (Graves´ Orbitopathy or Thyroid Eye Disease) Completed NCT01297699 Phase 3 Tocilizumab (RoActemra®);Sterile 0.9% Sodium Chloride
26 Trial of Rituximab for Graves' Ophthalmopathy Completed NCT00595335 Phase 2, Phase 3 Rituximab;Saline;Methylprednisolone
27 Efficacy and Safety of Cholestyramine and Prednisolone as Adjunctive Therapy in Treatment of Overt Hyperthyroidism Recruiting NCT03303053 Phase 3 Cholestyramine Powder 4g;Prednisolone;Standard treatment
28 Total Thyroidectomy Versus Thionamides in Patients With Moderate-to-Severe Graves' Ophthalmopathy Recruiting NCT03066076 Phase 3 Antithyroid Drug
29 Bupivacaine Injection of Eye Muscles to Treat Strabismus Recruiting NCT01616108 Phase 2, Phase 3 Bupivacaine
30 The Effect of Intravenous Glucocorticoids on the Tearfilm in Eyes With Thyroid-associated Ophthalmopathy Recruiting NCT01579539 Phase 3 Methylprednisolone;Esomeprazole
31 Analysis of Surface EKG Signals to Identify Myocardial Dysfunction in Patients at Risk for Coronary Artery Disease Recruiting NCT02560168 Phase 2, Phase 3
32 Early Levothyroxine Post Radioactive Iodine Active, not recruiting NCT01950260 Phase 2, Phase 3 Levothyroxine
33 Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study Not yet recruiting NCT03298867 Phase 3
34 The Effect of a New Antioxidant Combination (ASTED) on Mild Thyroid Eye Disease (TED) Not yet recruiting NCT02393183 Phase 2, Phase 3 ASTED
35 The Effect of a New Antioxidant Combination (ASTED) on Moderate to Severe Thyroid Eye Disease Not yet recruiting NCT02422368 Phase 2, Phase 3 Methylprednisolone + ASTED;Methylprednisolone +Placebo
36 Treatment of Graves´Ophthalmopathy With Diclofenac or Simvastatin (GO-DS) Not yet recruiting NCT03131726 Phase 3 Simvastatin 40mg;Diclofenac Potassium 50 MG
37 Role of the Microbiome in Graves' Orbitopathy Unknown status NCT02373995 Phase 1, Phase 2
38 Doxycycline Treatment in Mild Graves' Orbitopathy Unknown status NCT02203682 Phase 2 Doxycycline;placebo
39 Effects Of Oral Alfacalcidol On Maturation Of Dendritic Cells In Graves' Disease Patients Completed NCT02993302 Phase 2 1α-D3;Placebos
40 A Study to Evaluate the Safety and Effect of CFZ533 on Patients With Graves' Disease Completed NCT02713256 Phase 2 CFZ533
41 Radioactive Iodide Therapy for Pediatric Graves' Disease Completed NCT01269749 Phase 2 ATD Group
42 Rituximab in the Treatment of Graves' Disease Completed NCT00150111 Phase 1, Phase 2 Methimazole;Rituximab
43 rhTSH, Thyroid Size, and Radioiodine Therapy in Benign Goiter Completed NCT00145366 Phase 2 Recombinant human thyrotropin (Thyrogen)
44 Rituximab Treatment of Graves' Dysthyroid Ophthalmopathy Completed NCT00424151 Phase 1, Phase 2 Rituximab
45 Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy Completed NCT01727973 Phase 1, Phase 2 Doxycycline
46 Teprotumumab Treatment in Patients With Active Thyroid Eye Disease Completed NCT01868997 Phase 2 teprotumumab;normal saline
47 Neuropsychologic and Immunological Evaluation in Treatment of Thyroid Diseases. Is Selenium Efficient? Completed NCT01247077 Phase 2
48 Celecoxib for Thyroid Eye Disease Recruiting NCT02845336 Phase 2 Celecoxib;artificial tears
49 Dissonance Inpatient Relapse Prevention Program for Anorexia Nervosa Recruiting NCT01611220 Phase 2
50 A Safety and Tolerability Study of Otelixizumab in Thyroid Eye Disease Terminated NCT01114503 Phase 2 Otelixizumab - low dose;Otelixizumab - medium low dose;Otelixizumab - medium high dose;Otelixizumab - high dose;Otelixizumab;Methylprednisolone

Search NIH Clinical Center for Graves' Disease

Cochrane evidence based reviews: graves disease

Genetic Tests for Graves' Disease

Genetic tests related to Graves' Disease:

id Genetic test Affiliating Genes
1 Graves' Disease 29

Anatomical Context for Graves' Disease

MalaCards organs/tissues related to Graves' Disease:

39
Thyroid, Eye, T Cells, Bone, Skin, Heart, B Cells

Publications for Graves' Disease

Articles related to Graves' Disease:

(show top 50) (show all 1523)
id Title Authors Year
1
Thyrotropin-producing pituitary adenoma simultaneously existing with Graves' disease: a case report. ( 28061802 )
2017
2
A case of metastatic follicular thyroid carcinoma complicated with Graves' disease after total thyroidectomy. ( 28883260 )
2017
3
Annularly arranged nodular pretibial myxedema after 7-year treatment of Graves' disease. ( 28150342 )
2017
4
Glucose metabolism before and after radioiodine therapy of a patient with Graves' disease: Assessment by continuous glucose monitoring. ( 28781778 )
2017
5
Correlations of CTLA-4 Exon-1 49 A/G and Promoter Region 318a88C/T Polymorphisms with the Therapeutic Efficacy of (131) I Radionuclide in Graves' Disease in Chinese Han Population. ( 28776731 )
2017
6
Orbital flourine-18-fluorodeoxyglucose positron emission tomography in patients with Graves' disease for evaluation of active inflammation. ( 28863123 )
2017
7
Chylothorax Associated with Substernal Goiter in Graves' Disease Treated with Radioactive Iodine. ( 28835765 )
2017
8
Personalised immunomodulating treatments for Graves' disease: fact or fiction? ( 28804863 )
2017
9
Increased Cardiovascular Mortality and Morbidity in Patients Treated for Toxic Nodular Goiter Compared to Graves' Disease and Nontoxic Goiter. ( 28471268 )
2017
10
Piezosurgery in Modified Pterional Orbital Decompression Surgery in Graves Disease. ( 28705701 )
2017
11
Evaluation of the Efficacy of Standardized Uptake Value (SUV)-shape Scheme for Thyroid Volume Determination in Graves' Disease: A Comparison with Ultrasonography. ( 28840138 )
2017
12
Role of Different CD40 Polymorphisms in Graves' Disease and Hashimoto's Thyroiditis. ( 28742400 )
2017
13
ITM2A Expands Evidence for Genetic and Environmental Interaction in Graves Disease Pathogenesis. ( 27809695 )
2017
14
Protein oxidation and autoantibodies' reactivity against malondialdehyde and hydrogen peroxide-modified thyroid antigens in plasma of patients with Graves' disease and Hashimoto Thyroiditis. ( 28431875 )
2017
15
Hickam's dictum: Myasthenia Gravis presenting concurrently with Graves' disease. ( 28882932 )
2017
16
An acute phase reaction with intravenous bisphosphonate use in a patient with recently diagnosed Graves' disease. ( 28781829 )
2017
17
Histological Changes in Autoimmune Hepatitis with Graves' Disease: A Child Case Report. ( 28781316 )
2017
18
Establishment of a tear protein biomarker panel differentiating between Graves' disease with or without orbitopathy. ( 28419103 )
2017
19
Serum Free T3 to Free T4 Ratio as a Useful Indicator for Differentiating Destruction Induced Thyrotoxicosis from Graves' Disease. ( 28892954 )
2017
20
Thyrotoxic periodic paralysis as an initial presentation of Graves' disease in a Saudi patient. ( 28630226 )
2017
21
Low regulatory T cell and high IL-17 mRNA expression in a mouse Graves' disease model. ( 27822606 )
2017
22
Dr Google: The readability and accuracy of patient education websites for Graves' disease treatment. ( 28864099 )
2017
23
MST-4 and TRAF-6 expression in the peripheral blood mononuclear cells of patients with Graves' disease and its significance. ( 28219358 )
2017
24
Association of Human Leukocyte Antigens Class I and II with Graves' Disease in Iranian Population. ( 28919585 )
2017
25
Graves' Disease and Psychosis in a Young Woman: Pathophysiologic Considerations. ( 28906601 )
2017
26
Common phenotype and different non-HLA genes in Graves' disease and alopecia areata. ( 27810496 )
2017
27
Analysis of risk factors of rapid thyroidal radioiodine-131 turnover in Graves' disease patients. ( 28811561 )
2017
28
Thymic Hyperplasia Associated with Graves' Disease: Pathophysiology and Proposed Management Algorithm. ( 28578595 )
2017
29
MiR-346 and TRAb as Predicative Factors for Relapse in Graves' Disease Within One Year. ( 28192819 )
2017
30
Is Graves' disease a primary immunodeficiency? New immunological perspectives on an endocrine disease. ( 28942732 )
2017
31
Comparison of three competitive immunoassays for measurement of TSH receptor antibodies in patients with Graves' disease. ( 28737965 )
2017
32
Decreased Frequencies of Peripheral Blood CD4+CD25+CD127-Foxp3+ in Patients with Graves' Disease and Graves' Orbitopathy: Enhancing Effect of Insulin Growth Factor-1 on Treg Cells. ( 28222462 )
2017
33
Neonatal Graves' Disease with Maternal Hypothyroidism. ( 28948062 )
2017
34
Graves' Disease. ( 28076710 )
2017
35
Graves' Disease. ( 28079342 )
2017
36
Thyrotropin Receptor Epitope and Human Leukocyte Antigen in Graves' Disease. ( 27602020 )
2016
37
Controversies in the management of Graves' disease in children. ( 27153850 )
2016
38
A case of hypercalcaemic crisis secondary to coexistence of primary hyperparathyroidism and Graves' disease. ( 27941175 )
2016
39
Graves' Patient with Thymic Expression of Thyrotropin Receptors and Dynamic Changes in Thymic Hyperplasia Proportional to Graves' Disease Activity. ( 26996584 )
2016
40
Isolated Adrenocorticotropin Deficiency Concomitant with Graves' Disease: A Case Report and Literature Review. ( 27629962 )
2016
41
Graves' disease in a mediastinal mass presenting after total thyroidectomy for nontoxic multinodular goiter: a case report. ( 27029843 )
2016
42
Thyroidectomy for Graves' disease in children: Indications and complications. ( 27113266 )
2016
43
The Natural History of Subclinical Hyperthyroidism in Graves' Disease: The Rule of Thirds. ( 27090092 )
2016
44
Risk Factors of Lymphnode Metastasis in Patients with Thyroid <br/>Papillary Carcinoma Associated with Graves Disease. ( 27825413 )
2016
45
Thyrotoxic Periodic Paralysis and Polymorphisms of the ADRB2, AR, and GABRA3 Genes in Men with Graves Disease. ( 26676335 )
2016
46
Superior Mesenteric Artery Syndrome Complicated by Diabetic Ketoacidosis and Graves' Disease in Slowly Progressive Insulin Dependent Diabetes Mellitus (SPIDDM): A Case Report and a Review of the Literature. ( 27477411 )
2016
47
Differentiating Graves' disease from subacute thyroiditis using ratio of serum free triiodothyronine to free thyroxine. ( 27570620 )
2016
48
Proteomic analysis reveals aberrant expression of CALR and HSPA5 in thyroid tissues of Graves' disease. ( 27566407 )
2016
49
Excessive Cytosolic DNA Fragments as a Potential Trigger of Graves' Disease: An Encrypted Message Sent by Animal Models. ( 27895620 )
2016
50
Pooled genome wide association detects association upstream of FCRL3 with Graves' disease. ( 27863461 )
2016

Variations for Graves' Disease

Expression for Graves' Disease

Search GEO for disease gene expression data for Graves' Disease.

Pathways for Graves' Disease

Pathways related to Graves' Disease according to GeneCards Suite gene sharing:

(show all 28)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.22 CD40 FASLG HLA-DQA1 ICAM1 IFNG IL16
2
Show member pathways
12.63 FASLG HLA-DQA1 ICAM1 IFNG IL2RA IL4
3
Show member pathways
12.53 CD40 HLA-DQA1 IFNG IL2RA IL4
4 12.34 CD40 HLA-DQA1 ICAM1 IL2RA
5 12.34 CTLA4 FASLG IFNG IL2RA IL4 PTPN22
6
Show member pathways
12.33 SERPINA7 TG TPO TSHR
7
Show member pathways
12.3 CD40 CTLA4 HLA-DQA1 IL2RA
8 12.2 CD40 HLA-DQA1 ICAM1 IFNG
9
Show member pathways
12.14 CD40 HLA-DQA1 IFNG IL4
10
Show member pathways
12.1 CD40 CTLA4 FASLG HLA-DQA1 ICAM1 IFNG
11 11.99 CD40 CTLA4 HLA-DQA1 ICAM1
12 11.8 HLA-DQA1 IL2RA IL4
13
Show member pathways
11.79 FASLG IFNG IL2RA IL4
14 11.71 ICAM1 IFNG IL4
15 11.69 IFNG IL2RA IL4
16 11.66 CTLA4 HLA-DQA1 ICAM1 IFNG
17 11.63 CTLA4 HLA-DQA1 PTPN22
18
Show member pathways
11.6 FASLG IL2RA IL4
19
Show member pathways
11.55 FASLG IFNG IL2RA
20
Show member pathways
11.43 CTLA4 FASLG IFNG IL2RA IL4
21 11.42 CD40 ICAM1 IFNG
22 11.4 IFNG IL2RA IL4
23 11.36 FASLG ICAM1 IFNG
24
Show member pathways
11.27 FASLG IFNG IL2RA
25 11.2 FASLG ICAM1 IFNG
26 11.2 CD40 CTLA4 ICAM1 IL2RA IL4
27 11.08 CD40 IFNG IL2RA IL4
28 10.28 TG TPO TSHR

GO Terms for Graves' Disease

Cellular components related to Graves' Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.63 CD40 FASLG ICAM1 IL2RA TPO TSHR
2 extracellular space GO:0005615 9.56 CD40 FASLG ICAM1 IFNG IL16 IL4
3 external side of plasma membrane GO:0009897 9.17 CD40 CTLA4 FASLG ICAM1 IFNG IL2RA

Biological processes related to Graves' Disease according to GeneCards Suite gene sharing:

(show all 22)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.98 FASLG FGFR1OP IFNG IL4 TSHR
2 immune system process GO:0002376 9.97 CD40 CTLA4 HLA-DQA1 IL2RA PTPN22
3 regulation of immune response GO:0050776 9.8 CD40 ICAM1 IFNG IL4
4 response to lipopolysaccharide GO:0032496 9.73 CD40 FASLG ICAM1 PTPN22
5 apoptotic signaling pathway GO:0097190 9.71 CD40 FASLG UACA
6 interferon-gamma-mediated signaling pathway GO:0060333 9.7 HLA-DQA1 ICAM1 IFNG
7 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.69 CD40 IFNG IL4
8 positive regulation of T cell proliferation GO:0042102 9.65 IFNG IL2RA IL4
9 negative regulation of T cell activation GO:0050868 9.61 IL4 PTPN22
10 positive regulation of endothelial cell apoptotic process GO:2000353 9.6 CD40 FASLG
11 negative regulation of immune response GO:0050777 9.59 CTLA4 IL2RA
12 thyroid hormone generation GO:0006590 9.58 DIO2 TPO
13 regulation of NIK/NF-kappaB signaling GO:1901222 9.56 PTPN22 UACA
14 positive regulation of chemokine biosynthetic process GO:0045080 9.55 IFNG IL4
15 positive regulation of MHC class II biosynthetic process GO:0045348 9.46 IFNG IL4
16 defense response to protozoan GO:0042832 9.43 CD40 IFNG IL4
17 thyroid hormone metabolic process GO:0042403 9.4 DIO2 TG
18 positive regulation of B cell proliferation GO:0030890 9.37 CD40 IL4
19 hormone biosynthetic process GO:0042446 9.33 DIO2 TG TPO
20 inflammatory cell apoptotic process GO:0006925 9.32 FASLG IFNG
21 immune response GO:0006955 9.23 CD40 CTLA4 FASLG HLA-DQA1 IFNG IL16
22 positive regulation of isotype switching to IgG isotypes GO:0048304 9.13 CD40 IFNG IL4

Molecular functions related to Graves' Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 8.92 FASLG IFNG IL16 IL4

Sources for Graves' Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....